http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009504794-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 |
| filingDate | 2006-08-18^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-02-05^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2009504794-A |
| titleOfInvention | Triazolyl derivatives of azabicyclo [3.1.0] hexane as dopamine D3 receptor modulators |
| abstract | The present invention provides a compound of formula (IC): [Where: p is an integer ranging from 0 to 4; R 1 independently consists of halogen, hydroxy, cyano, C 1-4 alkyl, halo C 1-4 alkyl, C 1-4 alkoxy, halo C 1-4 alkoxy, C 1-4 alkanoyl or SF 5 Selected from the group; or corresponding to the group R 5 ; m 1 , m 2 , m 3 , and m 4 are 0; m 5 , m 6 and m 7 are each independently 0, 1 or 2, where the sum of m 5 , m 6 and m 7 is 1 or 2; R 6 is C 1-6 alkyl; R 7 is halogen, C 1-6 alkyl or haloC 1-6 alkyl; R 2 is hydrogen or C 1-4 alkyl; N is 2 or 3; X is S or —CH 2 —; R 3 is C 1-4 alkyl; R 4 is hydrogen, a phenyl group, a heterocyclyl group, a 5- or 6-membered aromatic heterocyclic group, or an 8- to 11-membered bicyclic group, any of which is halogen, cyano, C 1 Optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of -4 alkyl, halo C1-4 alkyl, C1-4 alkoxy and C1-4 alkanoyl; R 5 is isoxazolyl, —CH 2 —N-pyrrolyl, 1,1-dioxide-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl or 2-pyrrolidinonyl, wherein each group is halogen, cyano, Optionally substituted with 1 or 2 substituents selected from C 1-4 alkyl, halo C 1-4 alkyl, C 1-4 alkoxy or C 1-4 alkanoyl; However, when m 5 = m 6 = 1, R 7 is not chlorine] As a modulator of a novel compound or a salt thereof, a preparation method thereof, an intermediate used in the method, a pharmaceutical composition containing them, and a dopamine D 3 receptor, for example, a substance-related disorder as an antipsychotic drug, Or its use in therapy to treat cognitive impairment. |
| priorityDate | 2005-08-22^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 164 of 164.